Primary Immune Deficiency

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

NCT00719680 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.

4 Sites

21 Participants

Recruiting

2 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Contact CSL Behring for facility details

Centennial,Colorado,United States,80112

Contact CSL Behring for facility details

North Palm Beach,Florida,United States,33408

Contact CSL Behring for facility details

Indianapolis,Indiana,United States,46202

Contact CSL Behring for facility details

Dallas,Texas,United States,75230

Study Eligibility Criteria

Inclusion Criteria

* Subjects with primary humoral immunodeficiency who have participated in the study ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as defined by PAGID and ESID
* Women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening
* Written informed consent

Exclusion Criteria

* Ongoing serious bacterial infection at the time of screening
* Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma, and immunodeficiency with thymoma
* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration \> 0.2 g/L)
* Other significant medical conditions that could increase the risk to the patient
* Females who are pregnant, breast-feeding or planning a pregnancy during the course of the study
* A positive result at screening on any of the following viral markers: Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV)
* Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration \> 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR (NCT00419341)
* Creatinine concentration \> 1.5 times UNL at Completion Visit of study ZLB04_009CR (NCT00419341)
* Participation in a study with an investigational product other than IgPro20 within 3 months prior to enrollment
* Evidence of uncooperative attitude
* Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial
* Subjects who are employees at the investigational site, relatives or spouse of the investigator

Additional Studies

Additional studies can be found at ClinicalTrials.gov